Wendy R. Parulekar
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Association among tumor fraction, short/long fragment length, and PFS time. A and B, Kaplan–Meier curves of cfDNA tumor fraction cutoffs most significantly associated with poor PFS time for ( A ) baseline samples at 2% tumor fraction and ( B ) week 24 samples at 6% tumor fraction. C, Change in tumor fraction between baseline and week 12 associated with PFS. D and E, Kaplan–Meier curves of fragment length ratio cutoffs ( D ) at baseline and ( E ) week 12. F, Correlation between tumor fraction and short/long fragment length ratio at baseline.
Year:
2025
The randomized phase II MA.38 trial estimated the relative progression-free survival (PFS) associated with second-line endocrine therapy plus palbociclib administered on a 100 mg continuous daily dosing (CDD) schedule compared with the standard dose schedule (SDS) of 125 mg (days 1–21 of a 28-day cycle). A total of 180 patients were allocated 1:1 to protocol therapy. Molecular profiling was performed on the archival tissue and cell-free DNA (cfDNA) at enrollment, 3 months, and 6 months. The primary analysis for PFS demonstrated a similar outcome for the CDD versus SDS treatment strategy: HR = 0.93 (90% confidence interval, 0.66–1.30). Secondary efficacy measures for CDD versus SDS included the following: overall survival, HR = 1.07 (90% confidence interval, 0.67–1.69); response rate, 16.1% versus 18.0% ( P = 0.66); median duration of response, 4.2 months (range, 2.8–13.9 months) versus 5.6 months (range, 2.4–13.9 months; P = 0.86); and clinical benefit rate, 53.2% versus 57.3% ( P = 0.89). cfDNA profiling of the baseline enrollment sample prior to palbociclib commencement showed low tumor fraction (HR = 2.28; P = 9.9 × 10 −6 ); higher short/long fragment length ratios (HR = 1.19; P = 0.049) and cfDNA variants in FGFR4 (HR = 3.65; P = 0.012) were prognostic and associated with inferior PFS. Variants in TP53 (HR = 2.48; P = 0.006) and ESR1 (HR = 3.42; P = 0.005) detected at 12 weeks on treatment were also associated with poor PFS. CDD palbociclib 100 mg dosing was not associated with improved efficacy compared with the standard intermittent 125 mg dosing schedule. Additionally, we identified prognostic biomarkers in alignment with prior research and demonstrated the value of cfDNA dynamics, including fragment length ratios and tumor fraction as a measure of treatment response. Significance: A continuous 100 mg dosing schedule of palbociclib was tolerable but not associated with improved efficacy signals versus the standard intermittent 125 mg (days 1–21 of a 28-day cycle) schedule. Mutations detected in liquid biopsies and changes in cfDNA dynamics were linked to poor outcomes and may identify patients with treatment-resistant cancer.
Year:
2025
Figure S9. Association between tumour-fraction, short to long fragment length ratios and progression-free survival time. A) Hazard ratio between individuals above and below each tumour fraction cut-off at baseline (green), W12 (red) and W24 (yellow). Filled in points indicate significant hazard ratios. B) Hazard ratios of tumour fraction change between baseline and W12 cfDNA associated with progression-free survival at various cut-offs. Filled in points indicate significant hazard ratios. C) Cell-free DNA fragment length distribution between individuals with shorter and longer progression free survival time of three months. D) Hazard ratio of short to long fragment length ratio on progression free survival time using various cut-offs to divide short and long. Colours indicate cfDNA sampling time at baseline (green), W12 (red) and at W24 (yellow). Filled in points are significant log-rank p-values fragment length cut-offs.
Year:
2025
Figure S8. Summary of biological processes associated with PFS in baseline and W12 cfDNA plasma based on mutational profiles. (A-B) Forest plots summarize HR of mutations in genes among biological processes significantly associated with PFS among (A) baseline and (B) W12 samples.
Year:
2025
Pretreatment diagnostic tumor somatic variants and transcriptional signatures associated with PFS. A, Frequency of variants across breast cancer driver genes in pretreatment tumor biopsies. Colors indicate variant classification ( B ) VAF of detected single-nucleotide variants across samples. C, HRs of PFS associated with the presence of somatic variants in driver genes. D–F, Kaplan–Meier curves of genetic variants associated with shorter PFS time in ( D ) TP53 and ( E ) CDH1 . F–I, Kaplan–Meier curves of transcriptional signatures stratified by TP53 variant status associated with shorter PFS time for ( F ) HRD, ( G ) hypoxia, ( H ) androgen receptor, and ( I ) claudin low.
Year:
2025
MA.38 main trial results. A, CONSORT diagram. B and C, Results from the MA.38 trial for ( B ) PFS and ( C ) OS among patients in the CDS (blue) and SDS (red). AE, adverse event.
Year:
2025
Somatic variants detected in cfDNA associated with PFS time at baseline and first follow-up at week 12. A and B, Summary of genetic variants captured at ( A ) baseline prior to palbociclib treatment and at ( B ) week 12. Blue squares indicate the detection of a somatic variant in cfDNA for individuals. Barplot colors indicate variant classification. C and D, HR associated with PFS time for genetic variants detected at ( C ) baseline and at ( D ) week 12. Red points indicate gene variants significantly associated with PFS. E–I, Kaplan–Meier curves of mutations significantly associated with poor PFS time at ( E–G ) baseline in ( E ) SETD2 , ( F ) DDR2 , and ( G ) FGFR4 and ( H and I ) at week 12 in ( H ) TP53 and ( I ) ESR1 . J and K, Kaplan–Meier curves of mutations associated with poor PFS in groups of genes in the ( J ) DNA repair pathway and ( K ) MAPK cascade.
Year:
2025
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 randomized adjuvant breast cancer trial, metformin ( v placebo) did not affect invasive disease-free or overall survival. Here, we report metformin effects on the risk of new cancer. Between 2010 and 2013, 3,649 patients with breast cancer younger than 75 years without diabetes with high-risk T1-3, N0-3 M0 breast cancer (any estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2) were randomly assigned to metformin 850 mg orally twice a day or placebo twice a day for 5 years. New primary invasive cancers (outside the ipsilateral breast) developing as a first event were identified. Time to events was described by the competing risks method; two-sided likelihood ratio tests adjusting for age, BMI, smoking, and alcohol intake were used to compare metformin versus placebo arms. A total of 184 patients developed new invasive cancers: 102 metformin and 82 placebo, hazard ratio (HR), 1.25; 95% CI, 0.94 to 1.68; P = .13. These included 48 contralateral invasive breast cancers (27 metformin v 21 placebo), HR, 1.29; 95% CI, 0.72 to 2.27; P = .40 and 136 new nonbreast primary cancers (75 metformin v 61 placebo), HR, 1.24; 95% CI, 0.88 to 1.74; P = .21. Metformin did not reduce the risk of new cancer development in these nondiabetic patients with breast cancer.
Year:
2023
Collaborators (6)
Bingshu Chen
Professor
Queen's University
Philip Awadalla
Professor of Molecular Genetics and Director
University of Oxford
Karen A. Gelmon
The University of British Columbia
Trevor J. Pugh
Professor
University Health Network
Mark Clemons
University of Ottawa
Julie Lemieux
Clinical assistant professor
Laval University
Make your next move.
Prepare your application
Review drafts before you send them.